FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy

We studied whether maximum standardized uptake values (SUV) from [18 F] PET/CT predict clinical outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC). Eighty-four patients were treated prospectively with 74 Gy(RBE) proton therapy and concurrent chemotherapy. P...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Radiation oncology (London, England) England), 2012-08, Vol.7 (1), p.144-144, Article 144
Hauptverfasser:	Xiang, Zuo-Lin, Erasmus, Jeremy, Komaki, Ritsuko, Cox, James D, Chang, Joe Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - therapy Care and treatment Chemotherapy Combined Modality Therapy Disease-Free Survival Female Fluorodeoxyglucose F18 Health aspects Humans Kaplan-Meier Estimate Lung cancer, Non-small cell Lung cancer, Small cell Lung Neoplasms - diagnostic imaging Lung Neoplasms - mortality Lung Neoplasms - therapy Male Medical imaging Metastasis Middle Aged Multimodal Imaging Neoplasm Recurrence, Local - diagnostic imaging Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - therapy Neoplasm Staging Non-small cell lung cancer Oncology Patient outcomes PET imaging PET/CT imaging Positron-Emission Tomography Prognosis Prognostic factors Proportional Hazards Models Proton beam radiotherapy Proton Therapy Radiation therapy Radiopharmaceuticals Relapse Risk factors Sport-utility vehicles Standardized uptake value Studies Tomography, X-Ray Computed
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We studied whether maximum standardized uptake values (SUV) from [18 F] PET/CT predict clinical outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC). Eighty-four patients were treated prospectively with 74 Gy(RBE) proton therapy and concurrent chemotherapy. PET/CT scans were available before (SUV1) and within 6 months after (SUV2) treatment. The predictive value of clinical and PET/CT factors were analyzed with univariate and multivariate Cox regression models. Median survival time was 29.9 months. At 3 years, the local recurrence-free survival (LRFS) rate was 34.8%; distant metastasis-free survival (DMFS), 35.4%; progression-free survival (PFS), 31.2%; and overall survival (OS), 37.2%. Patients with SUV2 ≥3.6 (the median) had high rates of LR (p = 0.021). Of 12 clinicopathologic features evaluated in univariate analysis, only KPS, SUV1, and SUV2 predicted LRFS, DMFS, PFS, and OS (p
ISSN:	1748-717X 1748-717X
DOI:	10.1186/1748-717X-7-144